Abstracts

186 – SMART ART: A Randomized Clinical Trial of Adaptive Strategies for HIV Viral Suppression in S Africa

Background Differentiated care for HIV increases viral suppression (VS). Incentives and home or smart locker delivery of antiretroviral therapy (ART) overcome barriers and could increase VS, esp. among young people.  Methods We conducted an adaptive randomized trial, the SMART ART Study, of optimized person-centered clinic services compared to home or smart locker ART services in…

189 – Integrating HIV and Hypertension Care Improves Blood Pressure in Uganda: A Cluster Randomized Trial

Background For People Living with HIV (PLHIV) in Africa, improving hypertension (HTN) diagnosis and management is critical to sustaining the health gains achieved through antiretroviral therapy; however, resources to provide care for non-AIDS comorbidities are limited.  This study aimed to assess the effectiveness of a higher-resource vs. lower-resource strategy to integrate HIV and HTN care.…

196 – Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial

Background Pritelivir is a novel oral helicase-primase inhibitor, active against HSV-1 and HSV-2, including strains resistant to nucleoside analogues and foscarnet. PRIOH-1 evaluated the safety and efficacy of pritelivir vs. investigator’s choice therapy (ICT) in immunocompromised (IC) patients, including people living with HIV (PLHIV), with refractory herpes simplex virus (HSV) infection, with or without documented…

197 – Meningococcal B (4CMenB) Vaccination for the Prevention of Gonorrhea in Men Who Have Sex With Men

Background Neisseria gonorrhoeae has a significant global impact on sexual and reproductive health. No vaccines are currently licensed for prevention. However, a meta-analysis of observational studies reported that a meningococcal B (4CMenB) vaccine is associated with an estimated 38% reduced risk of incident N. gonorrhoeae infection. A single open-label randomized trial reported no statistically significant protection.   Methods…

101 – Molecular and Structural Determinants of MDA5 Sensing of HIV-1 Unspliced RNA

Background BACKGROUND: HIV-1 co-opts the transcriptional start site (TSS) promiscuity of host RNA polymerase II to generate two different unspliced viral RNAs (usRNA) with one or three guanosines at their 5’ ends, known as cap1G or cap3G RNA, respectively. Interestingly, the cap-sequestered, dimerization initiation site (DIS)-exposed cap1G RNAs preferentially function as viral genomic RNA (gRNA),…

104 – Genome-Wide HIV-Guided CRISPR Screen Identifies Novel Antiviral Factors Including Targets of Vpu

Background The interplay between viruses and their hosts is shaped by cellular restriction factors (RFs) that target nearly every step of the viral replication cycle. To overcome these defenses, viruses evolved countermeasures, such as the expression of accessory proteins. Many antiviral factors – and the viral mechanisms that antagonize them – remain unknown. To identify…

105 – Systematic Discovery of Pro- and Anti-HIV Host Factors in Primary Human CD4+ T Cells

Background Despite extensive efforts, significant gaps remain in our understanding of which host factors promote or restrict human immunodeficiency virus (HIV) infection in human CD4+ T cells. However, interrogating the determinants of HIV infection in primary human T cells has not been previously possible at a genome-wide scale due to challenges of in vitro infection of adequate…

106 – Defective HIV-1 Proviruses Express Env and Contribute to Soluble gp120 in the Plasma of PWH on ART

Background Although antiretroviral therapy (ART) efficiently suppresses HIV-1 replication, it fails to eradicate the virus due to a long-lived viral reservoir. Most proviruses detected in the blood of people with HIV (PWH) on ART are genetically defective. Their contribution to residual inflammation and immune dysfunction through the production of viral proteins remains understudied. We previously…

1077 – Machine Learning and Longitudinal Data to Predict Unsuppressed HIV Viral Load in Rwanda, 2020-2025

Background Machine learning (ML) with longitudinal data can identify people living with HIV (PLHIV) at risk of unsuppressed viral load (uVL) before failure occurs. By modeling dynamic relationships between repeated viral load measurements and other patient factors, we intend to capture the critical temporal patterns often overlooked in previous research. Early detection enables timely interventions, improving retention,…